CNS Pharmaceuticals (CNSP) FY2025 10-K Risk Factors: 6 New, 6 Dropped

What the changes say

The company faces going concern doubts and sufficient cash only into the third quarter of 2026.
Management shifted its pipeline strategy toward acquiring or licensing new neurology and oncology drug candidates.
Full-time employee headcount doubled from four to eight people alongside a complete executive leadership transition.

What changed since the prior 10-K

New

NewRisks Related to the Company’s Business and Industry
Our future success depends on our ability to identify, acquire or license new drug candidates, and we may not be successful in doing so
The company may fail to identify, acquire, or license new drug candidates on commercially reasonable terms due to intense competition.
NewRisks Related to the Company’s Business and Industry
Any drug candidates we acquire or license may require significant additional development, and there can be no assurance that such candidates will prove to be safe, effective or commercially viable
Acquired or licensed drug candidates may require substantial development, prove unsafe or ineffective, or harbor unknown liabilities.
NewRisks Related to the Company’s Business and Industry
We may not have access to sufficient capital to pursue acquisition or licensing opportunities, which could limit our ability to expand our pipeline
Limited financial resources and uncertain capital markets may prevent the company from pursuing pipeline expansion opportunities.
NewRisks Related to the Company’s Business and Industry
We estimate that we have sufficient capital to fund operations into the third quarter of 2026. We have no commitments for such additional needed financing and will likely be required to raise such financing through the sale of additional equity or debt securities
Existing cash is estimated to fund operations only into the third quarter of 2026, forcing future equity or debt sales.
NewRisks Related to the Company’s Business and Industry
We cannot be certain that any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market or commercialize them
The company has no approved products and depends entirely on securing regulatory approval from the FDA for future product candidates.
NewRisks Related to the Company’s Business and Industry
If a future product candidate is found to be unsafe or ineffective, we will not be able to obtain regulatory approval for it and our business would be materially and possibly irreparably harmed
Clinical trial variability in safety or efficacy would prevent regulatory approval and harm the business.

Dropped

DroppedRisks Related to the Company’s Business and Industry
Our success depends greatly on the success of TPI 287 and Berubicin’s development for the treatment of glioblastoma, and our pipeline of product candidates beyond this lead indication is extremely early stage and limited
DroppedRisks Related to the Company’s Business and Industry
Our business currently depends largely on the successful development and commercialization of TPI 287 and Berubicin. Our ability to generate revenue related to product sales, if ever, will depend on the successful development and regulatory approval of TPI 287 and Berubicin for the treatment of glioblastoma
DroppedRisks Related to the Company’s Business and Industry
If TPI 287 and Berubicin is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business would be materially and possibly irreparably harmed
Reliance on TPI 287 and Berubicin for glioblastoma treatment.
DroppedRisks Related to the Company’s Business and Industry
Our chief science officer is currently working for us on a part-time basis. Our chief executive officer and chief science officer, also provide services for other companies in our industry and such other positions may create conflicts of interest for such officers in the future
DroppedRisks Related to Our Common Stock
As an “emerging growth company” under the Jumpstart Our Business Startups Act, or JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements
Dependency on TPI 287 and Berubicin commercialization for revenue.
DroppedRisks Related to Our Common Stock
We intend to take advantage of all of these reduced reporting requirements and exemptions, other than the longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act

Reworded

93% rewrittenRisks Related to the Company’s Business and Industry
We will require substantial funding to execute our new corporate strategy, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations
Updated to reflect a new corporate strategy of acquiring investigational product candidates using cash, milestones, royalties, stock, or assumed liabilities.
Was: We will require substantial funding to complete our clinical trials, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations
83% rewrittenRisks Related to the Company’s Business and Industry
The report of our independent registered public accounting firm expresses substantial doubt about our ability to continue as a going concern. Such “going concern” opinion could impair our ability to obtain financing
Updated the audit year to 2025 and added that the company has never been profitable and has no product revenue.
48% rewrittenRisks Related to the Company’s Business and Industry
Although dependent on certain key personnel, we do not have any key man life insurance policies on any such people
Replaced the named executive team with a completely new leadership roster of Rami Levin, Eric Faulkner, Lynne Kelley, Steve O'Loughlin, and Dylan Wenke.
37% rewrittenRisks Related to Our Common Stock
Our current stockholders’ ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions
Retained the authorized share limits of 300,000,000 common and 5,000,000 preferred stock with minor stylistic edits.
36% rewrittenRisks Related to the Company’s Business and Industry
We will need to expand our operations and increase the size of our Company, and we may experience difficulties in managing growth
Updated full-time employee headcount from four employees to eight employees as of March 31, 2026.
30% rewrittenRisks Related to the Company’s Business and Industry
We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance
Removed specific trial references to TPI 287 and Berubicin from the description of historical operations.
29% rewrittenRisks Related to Our Common Stock
Failure to continue improving our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies
Updated the internal control annual assessment date to December 31, 2025.
27% rewrittenRisks Related to the Company’s Business and Industry
Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail
Added a statement that the cash investment strategy aims to minimize balances exceeding the FDIC insurance limit.

All 33 risk factors

Headings as the filing states them, in filing order.

Risks Related to the Company’s Business and Industry

01Our future success depends on our ability to identify, acquire or license new drug candidates, and we may not be successful in doing soNew
02Any drug candidates we acquire or license may require significant additional development, and there can be no assurance that such candidates will prove to be safe, effective or commercially viableNew
03We may not have access to sufficient capital to pursue acquisition or licensing opportunities, which could limit our ability to expand our pipelineNew
04We will require substantial funding to execute our new corporate strategy, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations93% rewritten
05We estimate that we have sufficient capital to fund operations into the third quarter of 2026. We have no commitments for such additional needed financing and will likely be required to raise such financing through the sale of additional equity or debt securitiesNew
06The report of our independent registered public accounting firm expresses substantial doubt about our ability to continue as a going concern. Such “going concern” opinion could impair our ability to obtain financing83% rewritten
07We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance30% rewritten
08We cannot be certain that any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market or commercialize themNew
09Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates
10We have never completed a clinical trial or submitted an NDA before, and any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval
11If a future product candidate is found to be unsafe or ineffective, we will not be able to obtain regulatory approval for it and our business would be materially and possibly irreparably harmedNew
12Interim or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
13Our product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales
14We have no sales, marketing or distribution experience and we will have to invest significant resources to develop those capabilities or enter into third-party sales and marketing arrangements, the problems with which could materially harm our business at any time
15We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates and our financial condition and operating results
16We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively
17We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights
18We may be subject to claims that our employees and contractors have wrongfully used or disclosed alleged trade secrets of their former employers
19If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished
20We will need to expand our operations and increase the size of our Company, and we may experience difficulties in managing growth36% rewritten
21We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants
22We do not expect that our insurance policies will cover all of our business exposures thus leaving us exposed to significant uninsured liabilities
23Although dependent on certain key personnel, we do not have any key man life insurance policies on any such people48% rewritten
24There may be limited suppliers for active pharmaceutical ingredients (“API”) used in our drug candidates. Problems with the third parties that manufacture the API used in our drug candidates, or in the supply chain between the manufacturer and CNS, may delay our clinical trials or subject us to liability
25We may not be able to recover from any catastrophic event affecting our suppliers
26We may be materially adversely affected in the event of cyber-based attacks, network security breaches, service interruptions, or data corruption
27Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail27% rewritten

Risks Related to Our Common Stock

28Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act has caused and may cause in the future our financial reports to be inaccurate
29Failure to continue improving our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies29% rewritten
30Our current stockholders’ ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions37% rewritten
31We may be required to repurchase certain of our warrants upon a fundamental transaction, which may prevent or deter a third party from acquiring us
32As a biotechnology company, we may be at an increased risk of securities class action litigation
33If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline

Other CNS Pharmaceuticals 10-Ks

FY2024 10-K risk factors
33 risks
The company relies heavily on the success and regulatory approval of only two drug candidates, Berubicin and TPI 287, for glioblastoma. Auditors have issued a going concern warning due to recurring operational losses and a need for substantial near-term capital. Management is extremely lean, with key executives working part-time and providing services to competing oncology entities.
Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.